IL217424A0 - Polypeptides selective for av beta3 integrin conjugated with a variant of human serum albumin (hsa)and pharmaceutical uses thereof - Google Patents

Polypeptides selective for av beta3 integrin conjugated with a variant of human serum albumin (hsa)and pharmaceutical uses thereof

Info

Publication number
IL217424A0
IL217424A0 IL217424A IL21742412A IL217424A0 IL 217424 A0 IL217424 A0 IL 217424A0 IL 217424 A IL217424 A IL 217424A IL 21742412 A IL21742412 A IL 21742412A IL 217424 A0 IL217424 A0 IL 217424A0
Authority
IL
Israel
Prior art keywords
hsa
variant
serum albumin
human serum
pharmaceutical uses
Prior art date
Application number
IL217424A
Other languages
English (en)
Original Assignee
Univ Nat Taiwan
Dcb Usa Llc
Univ Nat Cheng Kung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nat Taiwan, Dcb Usa Llc, Univ Nat Cheng Kung filed Critical Univ Nat Taiwan
Publication of IL217424A0 publication Critical patent/IL217424A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL217424A 2009-07-20 2012-01-08 Polypeptides selective for av beta3 integrin conjugated with a variant of human serum albumin (hsa)and pharmaceutical uses thereof IL217424A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22694509P 2009-07-20 2009-07-20
PCT/US2010/042423 WO2011011315A1 (en) 2009-07-20 2010-07-19 POLYPEPTIDES SELECTIVE FOR AV β3 INTEGRIN CONJUGATED WITH A VARIANT OF HUMAN SERUM ALBUMIN (HSA) AND PHARMACEUTICAL USES THEREOF

Publications (1)

Publication Number Publication Date
IL217424A0 true IL217424A0 (en) 2012-02-29

Family

ID=43465728

Family Applications (1)

Application Number Title Priority Date Filing Date
IL217424A IL217424A0 (en) 2009-07-20 2012-01-08 Polypeptides selective for av beta3 integrin conjugated with a variant of human serum albumin (hsa)and pharmaceutical uses thereof

Country Status (14)

Country Link
US (1) US20110015130A1 (enExample)
EP (1) EP2456454A4 (enExample)
JP (1) JP2012533631A (enExample)
KR (1) KR20120097481A (enExample)
CN (1) CN102470156A (enExample)
AR (1) AR077764A1 (enExample)
AU (1) AU2010276453A1 (enExample)
CA (1) CA2768360A1 (enExample)
IL (1) IL217424A0 (enExample)
MX (1) MX2012000895A (enExample)
NZ (1) NZ597580A (enExample)
RU (1) RU2547592C2 (enExample)
TW (1) TWI557224B (enExample)
WO (1) WO2011011315A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010092135A2 (en) 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Albumin variants and conjugates
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
US8357652B2 (en) * 2009-11-20 2013-01-22 Academia Sinica Anti-tumor fibrillar human serum albumin methods and compositions
KR20120130752A (ko) * 2009-12-23 2012-12-03 내셔널 타이완 유니버시티 혈관신생-관련된 안질환의 치료를 위한 조성물 및 방법
JP2013519392A (ja) 2010-02-16 2013-05-30 メディミューン，エルエルシー Ｈｓａ関連組成物および使用方法
CN106977608A (zh) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 白蛋白衍生物和变体
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
MX353816B (es) 2011-05-05 2018-01-30 Albumedix As Variantes de albumina.
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
MX2014010278A (es) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Variantes de albumina.
WO2014072481A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
EP3182988A4 (en) * 2014-08-22 2018-05-23 National Cheng Kung University Disintegrin variants and pharmaceutical uses thereof
CN108430489B (zh) * 2015-06-28 2022-03-25 新源生物科技股份有限公司 用于抑制血管新生的融合蛋白
WO2017027422A1 (en) 2015-08-07 2017-02-16 Alexo Therapeutics Inc. Constructs having a sirp-alpha domain or variant thereof
BR102016018074A2 (pt) * 2015-08-07 2021-11-16 ALX Oncology Inc. Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
AU2019368816B2 (en) 2018-10-22 2025-01-30 Janssen Pharmaceutica Nv Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof
KR20220044904A (ko) 2019-05-31 2022-04-12 알렉소 온콜로지 인크. 면역 관문 억제제와 병용하는 sirp 알파 fc 융합으로 암을 치료하는 방법
CN114845710A (zh) 2019-11-27 2022-08-02 Alx肿瘤生物技术公司 用于治疗癌症的组合疗法
CN117321208A (zh) * 2021-03-16 2023-12-29 Km生物医药股份公司 经修饰的人血清白蛋白-硫氧还蛋白融合体
BR112023022774A2 (pt) 2021-05-13 2024-01-02 Alx Oncology Inc Terapias de combinação para tratamento de câncer
WO2026022392A1 (en) * 2024-07-26 2026-01-29 Ospedale San Raffaele S.R.L. Peptide and conjugates thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) * 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1990015072A1 (en) * 1989-06-07 1990-12-13 Genentech, Inc. Platelet aggregation inhibitors and related molecules
US5525708A (en) * 1994-03-28 1996-06-11 Cytomed, Inc. Covalent dimer of kit ligand
AU2002339862A1 (en) * 2001-09-04 2003-05-26 Aventis Pharmaceuticals Inc. Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis
CA2465891C (en) * 2001-11-05 2012-05-15 Board Of Regents, The University Of Texas System Recombinant antibodies for the detection and neutralization of anthrax toxin
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
EP1534718A4 (en) * 2002-06-07 2006-06-07 Wisconsin Alumni Res Found CHEMICAL SYNTHESIS OF REAGENTS FOR PEPTIDE COUPLING
WO2005090400A1 (en) * 2004-03-18 2005-09-29 The University Court Of The University Of Glasgow Immunosuppressive cytokine
WO2008056961A1 (en) * 2006-11-10 2008-05-15 Boryung Pharmaceutical Co., Ltd A novel fusion protein, cell lines expressing the same and preparation method thereof
US8183201B2 (en) * 2006-12-26 2012-05-22 National Cheng Kung University Methods of treating αvβ3 integrin-associated diseases by administering polypeptides selective for αvβ3 integrin
US7943728B2 (en) * 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
KR20120130752A (ko) * 2009-12-23 2012-12-03 내셔널 타이완 유니버시티 혈관신생-관련된 안질환의 치료를 위한 조성물 및 방법

Also Published As

Publication number Publication date
NZ597580A (en) 2013-11-29
JP2012533631A (ja) 2012-12-27
US20110015130A1 (en) 2011-01-20
MX2012000895A (es) 2012-06-01
AU2010276453A1 (en) 2012-02-09
WO2011011315A1 (en) 2011-01-27
EP2456454A1 (en) 2012-05-30
CN102470156A (zh) 2012-05-23
TWI557224B (zh) 2016-11-11
KR20120097481A (ko) 2012-09-04
AR077764A1 (es) 2011-09-21
CA2768360A1 (en) 2011-01-27
EP2456454A4 (en) 2013-03-20
TW201107471A (en) 2011-03-01
RU2012105915A (ru) 2013-08-27
RU2547592C2 (ru) 2015-04-10

Similar Documents

Publication Publication Date Title
IL208598A0 (en) Human serum albumin linkers and conjugates thereof
IL237314A0 (en) Modified insulin polypeptides and their uses
ZA201107022B (en) Drug fusions and conjugates
IL232529A0 (en) Cytotoxic peptides and their drug-conjugated antibodies
ZA201006763B (en) Drug fusions and conjugates
IL221278A0 (en) Chlorotoxin polypeptides and conjugates and uses thereof
IL217121A0 (en) Antimicrobial fusion proteins and uses thereof
SG2014012918A (en) Albumin variants and conjugates
IL216800A0 (en) Artificial tears and therapeutic uses
SG10201406063XA (en) Drug fusions and conjugates with extended half life
GB0916576D0 (en) Polypeptides and uses thereof
EP2000483A4 (en) VEGF RECEPTOR FUSION PROTEIN AND APPLICATION THEREOF
ZA201200716B (en) Modified factor ix polypeptides and uses thereof
GB0916578D0 (en) Polypeptides and uses thereof
EP2588490A4 (en) SHORT AND D-AMINO ACID-CONTAINING POLYPEPTIDES FOR THERAPEUTIC CONJUGATES AND THEIR USES
EP2425311A4 (en) FOLDABLE SUPPORTING DEVICE AND COMPOSITE MATERIAL FOR THE PRODUCTION THEREOF
SI2483292T1 (sl) Variantni polipeptidi lovd in njihove uporabe
EP2456454A4 (en) FOR AV-3-INTEGRIN SELECTIVE POLYPEPTIDE AND PHARMACEUTICAL USES THEREOF ASSOCIATED WITH A HUMAN SERUM ALUMINUM (HSA) VARIATION
IL218474A (en) Fusion proteins and their method of production
PL2341047T3 (pl) Pochodna cykloheksanowa i jej farmaceutyczne zastosowanie
ZA201204516B (en) Modified bovine somatotropin polypeptides and their uses
GB0604966D0 (en) Medicaments and proteins
ZA201202203B (en) Drug fusions and conjugates with extended half life
IL206334A0 (en) Sarp-i fusion proteins and their use
DE102009038154A8 (de) Temperiereinheit und Batteriesystem umfassend eine solche Temperiereinheit